ADHERIUM LIMITED — AGM Information 2023

Nov 29, 2023

==> picture [174 x 37] intentionally omitted <==

Leading respiratory eHealth

Annual General Meeting 30 November 2023

==> picture [118 x 26] intentionally omitted <==

DISCLAIMER AND FORWARD-LOOKING STATEMENT

The material contained herein is of a general nature & has only been prepared as a presentation aid. This presentation does NOT contain all of the information that may be required for evaluating Adherium Limited ACN 605 352 510 (Adherium or the Company), its assets, prospects or potential opportunities.

These risks & uncertainties include, but are not limited to:

• i. the possible delays in & the outcome of product development

• ii. risks relating to possible partnering or other like arrangements

• iii. the potential for delays in regulatory approvals

This presentation may contain budget information, forecasts & forwardlooking statements in respect of which there is NO guarantee of future performance & which of themselves involve significant risks (both known & unknown). Actual results & future outcomes will in all likelihood differ from those outlined herein.

Forward-looking statements are statements that are not historical facts. Words such as “expect(s)”, “feel(s)”, “believe(s)”, “will”, “may”, “anticipate(s)” & similar expressions are intended to identify forwardlooking statements. These statements include, but are not limited to, statements regarding market size, future results, regulatory approvals, production targets, sales, staffing levels etc. All of such statements are subject to risks & uncertainties, many of which are difficult to predict & generally beyond the control of the Company, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking information & statements.

• iv. the unknown uptake & market penetration of any potential commercial products &

• v. other risks & uncertainties related to the Company’s prospects, assets / products & business strategy. This is particularly the case with companies such as Adherium which operate in the field of developing &

• commercializing medical devices & related services. You are cautioned not to place undue reliance on these forward- looking statements that speak only as of the date hereof, & we do not undertake any obligation to revise & disseminate forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of or non-occurrence of any events.

References to patient number targets to achieve a cash flow positive financial position are aspirational in nature. Additionally, there are a number of factors, both specific to Adherium & of a general nature, which may affect the future performance of Adherium. There is no guarantee that Adherium will achieve its stated objectives/milestones, that any of its forecasts will be met or that forward-looking statements will be realised.

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

2

WHY INVEST

TARGETING LARGE SCALE COMMERCIAL PARTNERSHIPS

CLEAR, NEAR-TERM PATHWAY TO CASH POSITIVE

==> picture [357 x 137] intentionally omitted <==

• Targeting large strategic partnerships to quickly scale

• Multiple B2B2C channels: hospitals, medical groups and insurance payors

• First remote patient monitoring revenues in FY23

• Objectives to cash flow positive with 80k patients onboard

MULTIPLE, REPLICABLE, LONG-TERM REVENUE PATHWAYS

FIRST MOVER ADVANTAGE

• Upfront revenue from sensor sales

• Recurring revenue from data fees and app and portal subscription

• Drug agnostic sensors with broad coverage of top 20 US inhaler brands

• Only US FDA 510(k) approved inhalation flow rate sensor on market

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

3

KEY DIFFERENTIATORS

Regulatory Only FDA 510(k) Clinically Improves adherence by 180% in children and 59% approvals cleared flow rate Validated in adults sensor on market Reduced severe UK, EU and Australia exacerbations by 61% in adults Extensive clinical evidence Big market US 51M patient Flexible Hailie sensors can be used addressable market with Hailie app and portal or broad platform Drug agnostic sensors integrated with external coverage third-party software Hailie adherence sensors cover 91% of US top 20 inhaler meds Hailie inhalation flow rate sensors cover 79% of US top 20 inhaler meds

==> picture [118 x 26] intentionally omitted <==

==> picture [369 x 252] intentionally omitted <==

©Adherium 2023

4

==> picture [809 x 540] intentionally omitted <==

©Adherium 2023

UNIQUE VALUE PROPOSITION

Established US Medicare, Medicaid and private insurance reimbursement environment

Doctors get paid for remote patient monitoring

Add NHS reimbursement initiatives

PATIENT TESTIMONIAL

“Our 8 year-old daughter had two exacerbations in the year before we started using Hailie . We’ve been using Hailie for nearly a year and a half now, and we haven’t had any exacerbations .”

John G.

Healthcare $34B annual ongoing cost burden to patients, health systems and savings insurance payors in US

PARTNER TESTIMONIAL

Patients benefit

Reduce ED and hospital admissions

Tailored care leads to fewer adverse events and better healthcare outcomes

“The Adherium platform of devices is ideally suited to helping patients and providers alike gain crucial insights into asthma care, barriers to adherence and technique, and improve outcomes.”

Dr Bill McCann

Appetite for telehealth driven by COVID-19

Allergy Partners, Chief Medical Officer

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

6

REVENUE STREAMS

==> picture [793 x 455] intentionally omitted <==

----- Start of picture text -----

TARGETING
US$15-$30/PER PATIENT
PER MONTH
Revenue inflow when
Sensor sales
patients onboarded
1
Adherium owns
device generated
+ data – future AI
data science
Data fees
revenue source
2
Providers and insurers pay
a recurring subscription fee
for data and platform
Per member
per month
3 subscription fees
Integration into health systems & on-going use makes revenue ‘sticky’
©Adherium 2023
----- End of picture text -----

==> picture [49 x 24] intentionally omitted <==

----- Start of picture text -----

Upfront
revenue
----- End of picture text -----

==> picture [56 x 25] intentionally omitted <==

----- Start of picture text -----

Recurring
revenue
----- End of picture text -----

==> picture [41 x 23] intentionally omitted <==

----- Start of picture text -----

7
----- End of picture text -----

TARGETED SALES CHANNELS

Priority: Large scale corporations which include networked hospital, outpatient and insurance services

==> picture [250 x 301] intentionally omitted <==

----- Start of picture text -----

MEDICAL GROUPS
Large scale medical groups
providing outpatient care
Priority: specialist clinics and
clinicians serving asthma and
COPD patients
----- End of picture text -----

==> picture [556 x 302] intentionally omitted <==

----- Start of picture text -----

PAYORS
HOSPITAL SYSTEMS
•
Large US hospital networks, e.g. US private insurers
• •
Commercial Self-insured employers
• Not-for-profit • US federal and state
• Government medical assistance
programs
----- End of picture text -----

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

8

NEAR TERM CASH FLOW POSITIVE

==> picture [199 x 33] intentionally omitted <==

Allergy Partners

• Largest US allergy & asthma practice based in North Carolina

• Over 300,000 patients across 130 sites in 20 states

• First patients onboarded Sep’23

• Hailie platform deployed to enable scaling

==> picture [164 x 36] intentionally omitted <==

SENTA Partners

• Major premier medical asthma & allergy specialty practice based in Georgia

• 48 locations in 6 states

• First patients onboarded Nov’23

==> picture [59 x 56] intentionally omitted <==

Agreements underpinning Adherium path to cash flow positive when 80k patients onboarded with continuing revenue build

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

9

TARGETING BROAD US PENETRATION TO SCALE

==> picture [749 x 436] intentionally omitted <==

Prospects/In Decision 1,067 Hospitals and 16,152 Sites of care

Confidential ©Adherium 2023

10

BUSINESS DEVELOPMENT PIPELINE

==> picture [537 x 441] intentionally omitted <==

----- Start of picture text -----

~600 US health systems & medical groups
81 prospective targets contacted
46 multiple meetings
8 in decision
2 signed and
1st patients
onboarded
80k patient cash
flow positive
milestone
----- End of picture text -----

With ~13.5% of health systems in the US contacted, large market still untapped Increasing sales and service staff

==> picture [281 x 75] intentionally omitted <==

----- Start of picture text -----

FY24 objective: sign 3 healthcare systems
& medical groups
FY25 objective: scaling to 10+ hospital
systems & medical groups
----- End of picture text -----

Confidential ©Adherium 2023

11

LOOKING AHEAD

ESTABLISHED & MARKET LEADING TECH

• Hailie system clinically validated & regulatory approved

• Drug agnostic sensors have broad market coverage

• Only FDA 510(k) approved next gen inhalation flow rate sensor on market

NEAR TERM CASH FLOW POSITIVE

• Revenue from sale of sensors and data generation and transmission with patient base for path to cash flow positive 80k patient objective

• Business strategy targeting and ramping up hospitals & medical groups

REPEATABLE, SCALEABLE BUSINESS MODEL

• Targeting large medical groups, hospital systems and insurance payors to generate scale

• Clinical workflow integration to Hailie platform creates sticky revenue

• Adherium owns data – for further commercial and clinical purposes

STRATEGY FOR MAJOR OPERATIONAL SCALE

• UK expansion leveraging NHS SRPI Award

• Plans to scale to 10+ hospital systems and medical group partners

• Future AI data sets and Software as a Medical Device (SaMD)

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

12

Confidential ©Adherium 2022 13

==> picture [118 x 26] intentionally omitted <==

HIGHLY EXPERIENCED LEADERSHIP TEAM

==> picture [111 x 129] intentionally omitted <==

Rick Legleiter Chief Executive Officer

• 20 years of experience in global healthcare & medical technology across the US, Australia, Europe & Asia

• Executive position at Universal Biosensors in Australia & Senior Vice President, Corporate Account Management positions at Siemens Healthcare in USA & Germany

==> picture [114 x 130] intentionally omitted <==

==> picture [104 x 130] intentionally omitted <==

==> picture [114 x 129] intentionally omitted <==

Francis White

Chris Leigh-Lancaster VP Product & Technology

Keven Gessner Executive VP – Advisor

Vice President, Global Business Development

• 25 years product

• 30 years experience in • 25 years of experience in Digital Health & Medical Pharmaceutical Industry Device commercialisation, • Led Digital Health for creating & building successful Teva & AstraZeneca US teams

  • development, commercialisation and AI across international medtech, consumer-tech, and agtech markets

• Led Digital Health for Teva & AstraZeneca US commercial

• Executive positions in Medtronic, Olympus Medical & Vice President, AliveCor Ltd, EMEA & OUS globally

• Most recent role was VP of US Digital Health, Marketing, & Market Access for Teva

• Led startup and scale-up organisations in Australia and New Zealand,

• Prior experience include • Development and 17 years at GSK & 5 commercialisation of years as CPA multiple award-winning products

==> picture [90 x 132] intentionally omitted <==

==> picture [115 x 130] intentionally omitted <==

Daniel Kaplon Chief Financial Officer

Tara Creaven-Capasso Vice President, Quality, Regulatory & Clinical Affairs

• Chartered Accountant with 25 years experience working in ASX-listed & private entities in healthcare, health

• Certified regulatory & quality professional with >20 years of health technology product development & commercial experience across the US, Europe, Asia, Australia & New Zealand

• technology, manufacturing & co-founded two medical device companies

• Leadership & advisor positions with private & publicly traded health technology companies

• Honours degree in

• Commerce, business degree in Transport & Logistics Management, & a Master of Entrepreneurship & Innovation (MEI)

==> picture [118 x 26] intentionally omitted <==

14

©Adherium 2023

BOARD: PROVEN COMMERCIAL, CLINICAL AND TECHNICAL LEADERSHIP

==> picture [102 x 122] intentionally omitted <==

==> picture [102 x 122] intentionally omitted <==

==> picture [101 x 123] intentionally omitted <==

==> picture [102 x 123] intentionally omitted <==

==> picture [102 x 123] intentionally omitted <==

Lou Panaccio

Independent Non-Executive Chair

Jeremy Curnock Cook Independent Non-Executive Director

George Baran

Non-Executive Director

Bruce McHarrie William Hunter Independent Independent Non-Executive Director Non-Executive Director

• Mr. Panaccio has • Over his 40-year career, extensive experience in Mr. Curnock Cook has the life sciences sector specialised in creating at the executive and value in emerging board level biotech enterprises

• He is currently a director at Avita Therapeutics, Sonic Healthcare, VGI Health Technology, NeuralDX and Haemokinesis.

• He is currently Managing Director of BioScience Managers and sits on the board of Avita Medical, Rex Bionics Pty, Summatix Pty Ltd, and SeaDragon Ltd.

• 35 years in the medical device industry and serves as Executive Chair of the Trudell Medical Limited Board of Directors as well as being a significant shareholder

• Mr. Baran is a Director of Sensory Technologies, Mozzaz Corporation, and Sky Medical Technology Inc.

• Mr. McHarrie is currently an independent director and consultant with over 25 years’ experience in the health and life sciences sectors

• Mr. McHarrie is currently an advisor to BioScience Managers and an independent consultant.

• Dr Hunter has

• extensive experience in commercializing medical device technologies

• He is currently President and CEO of Canary Medical Inc, Director of Rex Bionics and Industry Expert Advisor for BioScience Managers.

==> picture [118 x 26] intentionally omitted <==

©Adherium 2023

15

EXTENSIVE HAILIE TECHNOLOGY CLINICAL VALIDATION

Hailie technology referenced in >100 independent peer-reviewed publications involving > 13,000 patients.

==> picture [388 x 212] intentionally omitted <==

Hailie sensors have been used in 42 Across six independent validation studies clinical trials on over 13,000 adults and >97% designed to assess the accuracy of Hailie children Accuracy sensors in capturing medication usage

180% Increase

Adherence to preventative medication in study of children with asthma aged 6-15 years

61% Severe exacerbation in adults Decrease

==> picture [118 x 26] intentionally omitted <==

16

©Adherium 2023

Hailie sensor portfolio with US FDA 510(k) clearances, UK MHRA & AU TGA approval

New, next generation sensors with adherencee and physiological data capability such as inhalation flow rate

==> picture [85 x 121] intentionally omitted <==

==> picture [789 x 119] intentionally omitted <==

----- Start of picture text -----

for Anoro [®] Ellipta [®] /
Arnuity [®] Ellipta [®] / for Advair [®] HFA /
for ProAir [®] HFA /
for Symbicort [®] HFA Breo [®] Ellipta [®] / Flovent [®] HFA, and
Albuterol Sulfate HFA
(Next Gen RPM) Incruse [®] Ellipta [®] / for Ventolin [®] HFA
Trelegy [®] Ellipta [®]
(Next Gen RPM)
----- End of picture text -----

==> picture [83 x 125] intentionally omitted <==

==> picture [74 x 119] intentionally omitted <==

==> picture [468 x 224] intentionally omitted <==

----- Start of picture text -----

for Ventolin [®] HFA for Advair [®] HFA for Flovent [®] HFA
for Bevespi Aerosphere [®] for Advair [®] Diskus [®] / for Spiriva [® ] HandiHaler [®]
Flovent [®] Diskus [® ]
----- End of picture text -----

==> picture [83 x 113] intentionally omitted <==

==> picture [78 x 120] intentionally omitted <==

==> picture [85 x 29] intentionally omitted <==

==> picture [61 x 10] intentionally omitted <==

----- Start of picture text -----

for ProAir [®] HFA
----- End of picture text -----

==> picture [84 x 29] intentionally omitted <==

==> picture [78 x 11] intentionally omitted <==

----- Start of picture text -----

for Symbicort [®] HFA
----- End of picture text -----

Hailie sensors with adherence data capability with US, UK and AU approvals plus CE Mark

17

©Adherium 2023

Clinical Data and Trial References

1 Ruvuna L, Sood A. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med. 2020;41:315–27.

2 WHO Factsheet Asthma 2020

3 Most Recent National Asthma Data CDC - Prevalence & ER visits, October 2022

4 AZ Epidemiology data update Feb 2020

5 AAFA - Tips on How to Use Your Inhaler

6 Goldman Sachs - Digital Revolution Comes to US Healthcare

7 In adults with asthma, using the Hailie sensor with reminders for prescribed controller medication. Foster et al, J Allergy Clin Immunol 2014.

8 In children with asthma 6-15 yrs, with missed-dose medication reminders for prescribed controller medication. Chan et al, Lancet Respir Med 2015.

9 Understanding Asthma Statistics & Facts - Asthma Australia

10 van de Hei, Susanne J et al. “Long-Term Cost-Effectiveness of Digital Inhaler Adherence Technologies in Difficult-to-Treat Asthma.” The journal of allergy and clinical immunology. In practice vol. 11,10 (2023): 3064-3073.e15. doi:10.1016/j.jaip.2023.06.051

==> picture [118 x 26] intentionally omitted <==

18

©Adherium 2023